Myasthenia Gravis Therapeutics Market is Forecast to Show Slow Growth Until 2019

Wednesday 8 February 2012, Amsterdam

The report is an essential source of information and analysis on the global myasthenia gravis market. The report identifies the key trends shaping and driving the global myasthenia gravis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global myasthenia gravis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Myasthenia Gravis Therapeutics Market is Forecast to Show Slow Growth Until 2019

The estimates that the global myasthenia gravis therapeutics market was worth $62.9m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% over the next eight years to reach $92.2m by 2019. The growth in this market can be attributed to an increase in the myasthenia gravis prevalent population. The increase in the prevalent population is primarily due to a reduction in the mortality rate and the longer life expectancy of myasthenia gravis patients. Although the number of treated patients is increasing, the market is experiencing slow growth due to a lack of efficacious products that can treat the disease as opposed to providing symptomatic relief. The treatment landscape is not going to see any major change in the forecast period due to the lack of promising molecules in the late stage pipeline. The global myasthenia gravis market is expected to remain a low value market during the forecast period due to the domination of generics and off-label drugs.

See figure: Myasthenia Gravis Therapeutics Market, Global, Revenue and Forecasts ($m), 2006–2019

Current Treatment Options Leave a High Level of Unmet Need

The research indicates that the current treatment options are focused on offering symptomatic relief as opposed to treating the disease. The current treatment landscape consists of acetylcholine esterase (AChE) inhibitors (pyridostigmine bromide), steroid (prednisone) and immunosupressants such as azathioprine, cyclosporin A, and mycophenolate mofetil. The available treatment options are moderately successful in meeting the market demand. Even though the mortality rate has declined significantly after the introduction of these drugs, patient satisfaction is still low as the therapies only target symptoms of the disease. This is the reason for the high unmet need in the myasthenia gravis therapeutics market.

The Current Pipeline is Weak and No New Molecules with Novel Mechanisms of Action are Expected to Enter the Market During the Forecast Period (2011-2019)

A analysis shows that the current myasthenia gravis therapeutics pipeline is weak. The myasthenia gravis therapeutics pipeline consists of six molecules in the various stages of development.

Phase III contains one molecule, four molecules are in Phase II and one molecule is in the IND filed stage. The late stage pipeline contains only one molecule (prednisone) which is already used as an off label drug for the treatment of myasthenia gravis. The early stage pipeline seems promising, but these drugs are in the early stages of development and will not have an impact on the myasthenia gravis therapeutics market during the forecast period.